Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) is anticipated to post its resultson Wednesday, October 14th. Analysts expect the company to post earnings of ($200.00) per share for the quarter.
Hepion Pharmaceuticals (NASDAQ:HEPA – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($200.00) by $199.92.
Hepion Pharmaceuticals Stock Performance
Shares of HEPA stock opened at $0.12 on Monday. The stock has a market cap of $1.37 million, a P/E ratio of -0.03 and a beta of 1.52. The stock has a 50 day simple moving average of $0.08 and a 200 day simple moving average of $0.07. Hepion Pharmaceuticals has a 1 year low of $0.03 and a 1 year high of $0.13.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases and certain cancers. The company’s research has centered on rencofilstat, also known as CRV431, an orally administered cyclophilin inhibitor designed to address disease pathways involved in liver injury, fibrosis and tumor development.
Hepion has investigated rencofilstat in conditions including metabolic dysfunction-associated steatohepatitis (formerly known as nonalcoholic steatohepatitis), chronic hepatitis B and hepatocellular carcinoma.
Featured Stories
- Five stocks we like better than Hepion Pharmaceuticals
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
